This ultimate dynamic duo aims to celebrate life’s spontaneously sexy moments this spring, bringing together Astepro’s 30 minutes allergy relief and a unisex eau de toilette so you’re ready for anything, anywhere. Going beyond just seasonal allergy relief, the brand has created an ultra-limited-edition unisex eau de toilette, La Spontanéité. "Astepro® Allergy provides relief when my allergies are at their worst, so I don’t have to hold back and can be my spontaneous self." "I’ve been suffering from seasonal allergies for years and nothing makes me feel less sexy than compulsively sneezing," said actress Meghann Fahy. The fast, steroid-free allergy relief lets you be ready anytime and that’s a little boost to your confidence when you need it." "About every 7 in 10 allergy sufferers say allergies make them feel less attractive or admit it’s affected their love life. Let us know how this access is important for you."Astepro wants to change the way allergy sufferers approach life with allergies by giving them the ability to find relief starting in 30 minutes and jump into whatever comes their way," explains Catherine Vennat, General Manager, and Vice-President, US Marketing Allergy, Cough & Cold at Bayer. Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. FundingNational Institute of Allergy and Infectious Diseases and the Bill & Melinda Gates Foundation. Consideration of the PAF and NNT can aid in discussion of the benefits and risks of pre-exposure prophylaxis with MSM and transgender women. Substance use history and testing for STIs should also inform individual decisions to start pre-exposure prophylaxis. InterpretationPre-exposure prophylaxis may be most effective at a population level if targeted toward MSM and transgender women who report receptive anal intercourse without a condom, even if they perceive their partners to be HIV negative. Having one partner and insertive anal sex without a condom had the highest NNTs (100 and 77, respectively). NNTs were lowest for MSM and transgender women self-reporting receptive anal intercourse without a condom (NNT 36), cocaine use (12), or a sexually transmitted infection (41). The overall NNT per year for the cohort was 62 (95% CI 44-147). Most of this risk came from receptive anal intercourse without a condom with partners with unknown serostatus (PAF 53%, prevalence 54%, AHR 4♷6, 95% CI 1♴4-15♷1) by contrast, the PAF for receptive anal intercourse without a condom with an HIV-positive partner was 1% (prevalence 1%, AHR 7♱1, 95% CI 0♷0-72♷5). The overall PAF for MSM and transgender women reporting receptive anal intercourse without a condom was 64% (prevalence 60%). Participants reporting receptive anal intercourse without a condom seroconverted significantly more often than those reporting no anal sex without a condom (adjusted hazard ratio 5♱1, 95% CI 1♵5-16♷9). 83 of 1248 patients in the placebo group became infected with HIV during follow-up. Of the 2499 MSM and transgender women in the iPrEx trial, 1251 were assigned to pre-exposure prophylaxis and 1248 to placebo. FindingsPatients were enrolled between July 10, 2007, and Dec 17, 2009, and were followed up until Nov 21, 2010. The iPrEx trial is registered with, NCT00458393. We calculated the association between demographic and risk behaviour during screening and subsequent seroconversion among placebo recipients using a Poisson model, and we calculated the PAF and NNT for risk behaviour subgroups. Participants were randomly assigned (1:1) to receive either a pill with active pre-exposure prophylaxis or placebo, taken daily. Participants aged 18 years or older who were male at birth were enrolled from 11 trial sites in Brazil, Ecuador, Peru, South Africa, Thailand, and the USA. MethodsThe iPrEx study was a randomised controlled efficacy trial of pre-exposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine in 2499 men who have sex with men (MSM) and transgender women. We aimed to estimate the PAF and NNT of participants in the iPrEx (Pre-Exposure Prophylaxis Initiative) trial. BackgroundFor maximum effect pre-exposure prophylaxis should be targeted to the subpopulations that account for the largest proportion of infections (population-attributable fraction ) and for whom the number needed to treat (NNT) to prevent infection is lowest.
0 Comments
Leave a Reply. |